Literature DB >> 17172378

Dengue hemorrhagic Fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-2002.

Mayling Alvarez1, Rosmari Rodriguez-Roche, Lídice Bernardo, Susana Vázquez, Luis Morier, Daniel Gonzalez, Osvaldo Castro, Gustavo Kouri, Scott B Halstead, Maria G Guzman.   

Abstract

A dengue epidemic caused by dengue virus 3 (DENV-3) occurred in Cuba in 2001-2002. It included cases of dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). We report neutralizing antibody studies on sera from 54 of 78 DHF/DSS patients that provide evidence of infections occurring in the sequence DENV-1 followed by DENV-3. No sera showed infection in the sequence DENV-2 followed by DENV-3. Some sera showed a pattern of infection in the sequence DENV-1 followed by DENV-2 and then DENV-3. However definitive categorization of a tertiary infection was not possible because of broadly reactive antibodies, which could have been raised by infections in the sequence DENV-1 then DENV-3.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17172378

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  49 in total

Review 1.  Dengue: a continuing global threat.

Authors:  Maria G Guzman; Scott B Halstead; Harvey Artsob; Philippe Buchy; Jeremy Farrar; Duane J Gubler; Elizabeth Hunsperger; Axel Kroeger; Harold S Margolis; Eric Martínez; Michael B Nathan; Jose Luis Pelegrino; Cameron Simmons; Sutee Yoksan; Rosanna W Peeling
Journal:  Nat Rev Microbiol       Date:  2010-12       Impact factor: 60.633

2.  Anthracene-based inhibitors of dengue virus NS2B-NS3 protease.

Authors:  Suzanne M Tomlinson; Stanley J Watowich
Journal:  Antiviral Res       Date:  2010-12-23       Impact factor: 5.970

3.  Dengue: where are we today?

Authors:  Maria Guadalupe Guzman; Susana Vázquez; Gustavo Kouri
Journal:  Malays J Med Sci       Date:  2009-07

4.  Temperature-dependent production of pseudoinfectious dengue reporter virus particles by complementation.

Authors:  Camilo Ansarah-Sobrinho; Steevenson Nelson; Christiane A Jost; Stephen S Whitehead; Theodore C Pierson
Journal:  Virology       Date:  2008-09-17       Impact factor: 3.616

5.  Variation in inflammatory/regulatory cytokines in secondary, tertiary, and quaternary challenges with dengue virus.

Authors:  Beatriz Sierra; Ana B Pérez; Mayling Alvarez; Gissel García; Katrin Vogt; Eglys Aguirre; Kathrin Schmolke; Hans-Dieter Volk; María G Guzmán
Journal:  Am J Trop Med Hyg       Date:  2012-07-16       Impact factor: 2.345

6.  Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity.

Authors:  Molly OhAinle; Angel Balmaseda; Alexander R Macalalad; Yolanda Tellez; Michael C Zody; Saira Saborío; Andrea Nuñez; Niall J Lennon; Bruce W Birren; Aubree Gordon; Matthew R Henn; Eva Harris
Journal:  Sci Transl Med       Date:  2011-12-21       Impact factor: 17.956

7.  Use of parallel validation high-throughput screens to reduce false positives and identify novel dengue NS2B-NS3 protease inhibitors.

Authors:  Suzanne M Tomlinson; Stanley J Watowich
Journal:  Antiviral Res       Date:  2011-12-13       Impact factor: 5.970

8.  Dengue viral infections.

Authors:  Padmalal Gurugama; Pankaj Garg; Jennifer Perera; Ananda Wijewickrama; Suranjith L Seneviratne
Journal:  Indian J Dermatol       Date:  2010       Impact factor: 1.494

Review 9.  Structure-based discovery of dengue virus protease inhibitors.

Authors:  Suzanne M Tomlinson; Robert D Malmstrom; Andrew Russo; Niklaus Mueller; Yuan-Ping Pang; Stanley J Watowich
Journal:  Antiviral Res       Date:  2009-02-21       Impact factor: 5.970

10.  Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II.

Authors:  Chih-Yun Lai; Wen-Yang Tsai; Su-Ru Lin; Chuan-Liang Kao; Hsien-Ping Hu; Chwan-Chuen King; Han-Chung Wu; Gwong-Jen Chang; Wei-Kung Wang
Journal:  J Virol       Date:  2008-04-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.